PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “POTASSIUM IODIDE”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 91 records · Page 5Linked to original sources
PubMed1990

Iodine in milk and meat of dairy cows fed different amounts of potassium iodide or ethylenediamine dihydroiodide.

Relationships between I intake by lactating Holstein cows and iodine concentrations in milk and meat were investigated. Six treatment groups with seven cows assigned to each treatment were fed a basal diet containing .8 mg I/kg alone or supplemented with I at 1, 2, or 4 mg/kg in four 5-wk periods. Basal alone was fed in the first and third periods and the I supplement was potassium iodide in the second period and ethylenediamine dihydroiodide in the fourth period. Iodine concentrations in milk increased with each increase in dietary I from 205 ng/ml for basal periods to 404, 477, and 757 ng/ml when 1, 2, or 4 mg/kg I was fed as potassium iodide; and 467, 535, and 869 ng/ml when 1, 2, or 4 mg/kg I was fed as ethylenediamine dihydroiodide. Concentrations of I in skeletal muscle after the fourth period were not affected by 2 mg/kg I and only increased from 166 to 199 ng/g when supplemental I was 4 mg/kg. Moderate changes in dietary I are quickly reflected in milk I, but I in meat is relatively stable.

Animals↗
PubMed1993

[Determination of potassium iodide in Polish edible salt].

The purpose of the study was to assess the correctness of salt iodination and its distribution in Poland. The subject of the study was salt for human consumption iodinated or not, according to Polish norm PN-88/C-84081/02 "Sól (chlorek sodowy). Requirements. Salt samples were taken from retail shops or stores in 36 provinces. The study was carried out in the years 1992-1993 according to PN-80/C-84081.35 "Sól (chlorek sodowy) standard. Potassium iodide was determined by photo-colorimetry. The total number of studied salt samples was 3418, including 2440 samples of iodinated salt. The per cent of samples with proper content of potassium iodide was from 30% to 50% depending on the producer. The study demonstrated that in most cases the process of salt iodination is done incorrectly.

Poland↗
PubMed2003

Severe livedo vasculitis treated with potassium iodide.

A young woman presenting severe livedo vasculitis (LV) was successfully treated with potassium iodide (KI). Previous attempts to cure her disorder with corticosteroids, low-dose aspirin, and azathioprine in various combinations had failed. To our knowledge, this is the first report of LV treated with KI.

Adult↗
PubMed1978

[Effect of potassium iodide and perchlorate on the process of thyroid hormone secretion].

The influence of potassium iodide and perchlorate on the parameters characterizing the thypoid hormones secretion, such as the cAMP level in the gland tissue and the number of intracellular colloid droplets under condition of stimulation by thyrotropic hormone was studied. It was shown that the abovementioned parameters were depressed by an excess of iodide, but perchlorate administration prevented the inhibitory effect of iodide. The results obtained favour the conception on the sensitivity of the thyroid adenylate cyclase system to the organic iodine concentration. Apparently and excess of iodide depressed the capacity of perchlorate to influence its concentration in the gland, and thereby the process of iodine organification and of the thyroid hormone secretion maintained at the optimal leve.

Animals↗
PubMedDate not supplied

Predistribution of potassium iodide--the Tennessee experience.

Tennessee public health officials made a decision to predistribute potassium iodide tablets (KI) to householders in the vicinity of a nuclear powerplant. The tablets would be stored until needed in the event of a radiation emergency. The officials believed that it was important to have the option available as a means of protecting nearby residents. KI, ingested before or soon after exposure to radioactive iodine, can act as a thyroid blocker to protect the gland from accepting further iodine and, therefore, the radiation. A pilot project was undertaken to deliver, door to door, a package that contained KI tablets in sufficient quantity to supply a starter dose to each member of households within a 5-mile radius of the Sequoyah nuclear powerplant near Chattanooga. The package consisted of a vial of 14 130-mg tablets and a package insert from the manufacturer enclosed in a larger vial with a childproof cap. Home visitors who delivered the vials were professionals from the local public health departments, especially trained to answer questions about the project. About 66 percent of 5,591 homes accepted the medication. Extensive coverage of the project by information media was helpful in explaining local emergency plans as well as the KI distribution to the public.

Disaster Planning↗
PubMed1996

Treatment of cutaneous sporotrichosis with one daily dose of potassium iodide.

BACKGROUND: Recommended treatment for cutaneous sporotrichosis consists of a saturated solution of potassium iodide (SSKI) administered in three daily doses (tid). Because compliance with this regimen has been a problem in our previous experience, we evaluated the use of one daily (qd) full dose of SSKI. METHODS: Patients with culture-confirmed cutaneous sporotrichosis were entered in a randomized, nonblinded study to compare the safety and efficacy of qd vs. tid dosage of SSKI. RESULTS: Fifty-seven patients were enrolled to receive either qd (29) or tid (28) SSKI. Three (1 in the qd and 2 in the tid group) were not compliant with the assigned regimen. Side effects were common but mild in both treatment groups (61% in the qd and 42% in the tid group, P = 0.17); treatment had to be discontinued because of side effects in 3 cases (2 in the qd and 1 in the tid group). Overall 26 (89.6%) and 25 (89.2%) of the individuals initially assigned to the qd and tid dosing schedule, respectively, were cured by the treatment. No relapse was detected after 45 days of follow-up. CONCLUSION: These findings suggest that a single daily full dose of SSKI appears to be appropriate therapy for cutaneous sporotrichosis; further studies with larger numbers of patients are required.

Adolescent↗
PubMed1984

Developmental toxicity and psychotoxicity of potassium iodide in rats: a case for the inclusion of behaviour in toxicological assessment.

Potassium iodide (KI) was fed to male and female rats before and during breeding, to females only during gestation and lactation, and to their offspring after weaning (day 21 after birth) through to day 90, at levels of 0, 0.025, 0.05 or 0.1% (w/w) of the diet. Dams in a fifth group (positive controls) were given 4 mg/kg ip of the anti-mitotic/cytotoxic drug 5-azacytidine on day 17 of gestation. All offspring were reared by their natural dams and were evaluated blind with respect to treatment in a battery of standardized behavioural tests between 3 and 90 days of age. KI produced no significant reductions in parental body weight or food consumption, though it significantly reduced litter size and increased offspring mortality at the highest dose, and decreased weight gain at the two highest doses throughout the first 90 days after birth. Functionally, KI delayed auditory startle at the two highest doses, delayed olfactory orientation to the home-cage scent at the middle dose and decreased female running-wheel activity at all dose levels. In rats killed on day 90 after birth KI reduced brain and body weight at a dose of 0.1% of the diet, and reduced body but not brain weight at a dose of 0.05% of the diet. No significant effect was found on absolute or relative thyroid weight at 90 days of age. Several additional behavioural effects were observed in the low-dose KI group, but because these effects were not dose-dependent, they were not regarded as reliable. 5-Azacytidine produced evidence of substantially greater developmental toxicity than KI. It was concluded that KI produced evidence of developmental toxicity consistent with a picture of impaired thyroid function. The inclusion of tests of functional development added useful evidence to the overall picture of KI developmental toxicity.

Administration, Oral↗
PubMed1994

Wegener's granulomatosis successfully treated with prednisolone and potassium iodide.

Wegener's granulomatosis has traditionally been treated with steroids and cyclophosphamide. We used potassium iodide in conjunction with prednisolone to treat a patient with a limited form of this disease who had gangrenous rhinitis and skin involvement including necrotic papules and ulcerations. After three months of this therapy, the mucosal and cutaneous lesions had almost completely disappeared.

Drug Therapy, Combination↗
PubMed2003

[Efficacy of thyroxine and potassium iodide treatment of benign nodular thyroid lesions].

AIM: To study efficacy of thyroxine (TX) and potassium iodide (PI) in the treatment of benign nodular thyroid lesions (BNTL). MATERIAL AND METHODS: 118 patients with BNTL (colloid or colloid hypercellular as shown by thin needle aspiration biopsy, 'cold" or "warm" by scyntigraphy findings) were randomized into two groups: 59 patients were given thyroxin and the other 59 patients PI. The day dose of TX (75-150 mcg) was prescribed according to serum concentration of TTH trying to diminish it to 0.5 mIU/l and lower. PI dose was 200 mcg/day. Most of the patients were treated for 6 months. The response was evaluated with ultrasound investigation which measured thyroid volume, the size and number of the nodes in it before and in the end of therapy. The treatment was found effective if the dominant node decreased in size by 50% and more compared to pretreatment values. RESULTS: The size of the dominant node decreased by 50% and more in 14 of 59 (23.73%) patients on TX and in 20 of 59 (33.90%) patients on PI. Both TX and PI prevented growth of the dominant node size and number of the nodes in approximately 2/3 cases. TX was more effective in young patients (40.92 +/- 3.45 years) vs older ones (47.50 +/- 1.46 years, p = 0.047) and patients with colloid nodes. PI was more effective in patients with shorter node existence (3.93 +/- 1.21 and 8.59 +/- 1.74 months, p = 0.02). TX reduced thyroid volume from 20.42 +/- 1.69 to 15.18 +/- 1.30 ml (p = 0.001), PI--from 18.34 +/- 1.57 to 15.36 +/- 1.25 ml (p = 0.001). CONCLUSION: TX and PI can inhibit or prevent the growth of thyroid benign nodes in approximately 2/3 patients especially in young patients with colloid nodes (TX) and in short existence of the node (PI).

Adolescent↗
PubMedDate not supplied

[Hypothyroidism following intermittent administration of potassium iodide].

Iodide-induced hypothyroidism with high TSH and low T4 under long term potassium iodide medication was observed in a toddler suffering from chronic wheezy bronchitis -- in spite of intermittent application. The pathophysiology of iodide-induced hypothyroidism and the apparent immaturity of adaptation to high exogenous iodide in newborn and infants are discussed.

Bronchitis↗
PubMed1977

Hypercalcemic effect of potassium iodide on serum calcium in domestic fowl.

Five experiments were conducted to determine the influence of potassium iodide (KI) on serum calcium in the laying hen. Serum calcium was significantly increased when hens were fed a diet containing 5000 p.p.m. I as KI. This occurred even though feed consumption, egg production and size of ovary and oviduct were significantly decreased. In some hens fed KI, serum calcium was increased to as high as 70 mg. %, a 163% increase. Most of the increase was in the form of non-diffusible calcium. Hens fed a diet containing 0.05% calcium had significantly reduced serum calcium values. When these calcium-deficient hens were fed 5000 p.p.m. I as KI, a significant increase in serum calcium occurred within 3 days and within 7 days their average serum calcium value was significantly greater than that of hens fed a diet containing 3.00% calcium. A combination of KI plus estradiol was significantly more effective in increasing serum calcium than was either compound alone. Although these data gave no indication as to the mechanism of action of KI on serum calcium they do offer a new model in which to study calcium metabolism in the laying hen.

Animals↗
PubMed2000

Potassium iodide in dermatology: a 19th century drug for the 21st century-uses, pharmacology, adverse effects, and contraindications.

Potassium iodide (KI) is a useful drug in the dermatologic armamentarium. It is successfully used for inflammatory dermatoses, most notably erythema nodosum, subacute nodular migratory panniculitis, nodular vasculitis, erythema multiforme, and Sweet's syndrome. KI is also successfully used for cutaneous and lymphocutaneous sporotrichosis. The precise mechanism by which KI acts is unknown. Although many minor side effects are common with this drug, major side effects can occur in pregnant patients and those with a history of kidney or thyroid disease. This article reviews the pharmacology, mechanism of action, indications, contraindications, and adverse effects of KI as a therapeutic agent.

Humans↗
PubMed2000

Studies on the carcinogenicity of potassium iodide in F344 rats.

A chronic toxicity and carcinogenicity study, in which male and female F344/DuCrj rats were given potassium iodide (KI) in the drinking water at concentrations of 0, 10, 100 or 1000 ppm for 104 weeks, and a two-stage carcinogenicity study of application at 0 or 1000 ppm for 83 weeks following a single injection of N-bis(2-hydroxypropyl)nitrosamine (DHPN), were conducted. In the former, squamous cell carcinomas were induced in the salivary glands of the 1000 ppm group, but no tumors were observed in the thyroid. In the two-stage carcinogenicity study, thyroidal weights and the incidence of thyroid tumors derived from the follicular epithelium were significantly increased in the DHPN+KI as compared with the DHPN alone group. The results of our studies suggest that excess KI has a thyroid tumor-promoting effect, but KI per se does not induce thyroid tumors in rats. In the salivary gland, KI was suggested to have carcinogenic potential via an epigenetic mechanism, only active at a high dose.

Animals↗
PubMed2001

Acute cochleovestibular toxicity due to topical application of potassium iodide.

We present a case report of a patient who suffered from an acute cochleovestibular deficit after topical application of potassium iodide solution into the left ear. Although the vestibular symptoms progressively disappeared, severe sensorineural hearing loss persisted after treatment with hyperbaric oxygen therapy and intravenous administration of corticosteroids and vasodilating agents. The mechanisms of ototoxicity after topical application of solutions are discussed with emphasis on the particular features of the present case: a patulous Eustachian tube syndrome and the presence of a tympanostomy tube in the left ear.

Administration, Topical↗
PubMed1980

The potassium iodide patch test in the dermatitis herpetiformis in relation to treatment with a gluten-free diet and dapsone.

The potassium iodide patch test was studied in twenty-six patients with dermatitis herpetiformis. Histological assessment was found more sensitive than clinical. All of five patients with active disease and not on treatment had a positive test, whereas only two of six patients taking a gluten-free diet (GFD) and one of eight taking dapsone were positive. In another two patients taking a GFD, but in whom the diet had not been strict, the test was positive. All three patients in remission and both patients with the linear pattern of IgA (but with active disease) were negative. Immunofluorescence studies showed no difference in the presence, quantity, or distribution of immunoglobulin, complement or fibrinogen between the patch test site and uninvolved skin, or in the uninvolved skin between patients with and without active lesions.

Dapsone↗